ImmuCell Corporation (ICCC) financial statements (2021 and earlier)

Company profile

Business Address 56 EVERGREEN DR
PORTLAND, ME 04103
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,9465,9118,1956,9998,7749,5559,971
Cash and cash equivalents6,9503,9186,2036,5056,2932,3551,296
Short-term investments9961,9931,9924942,4817,2008,675
Receivables1,8481,5809831,9081,637902935
Inventory, net of allowances, customer advances and progress billings2,0932,0911,8931,5982,5182,6812,492
Inventory2,0932,0911,8931,5982,5182,6812,492
Prepaid expense253321234406218267190
Other undisclosed current assets1734183741221465
Total current assets:12,1579,93711,32310,94813,18913,62514,053
Noncurrent Assets
Operating lease, right-of-use asset1,2201,2471,2791,305   
Property, plant and equipment26,75527,18026,43326,17325,26624,97925,130
Intangible assets, net (including goodwill)191196201205210215220
Goodwill96969696969696
Intangible assets, net (excluding goodwill)96100105110115119124
Restricted cash and investments 1,4021,4011,400   
Other noncurrent assets2625242227297
Total noncurrent assets:28,19330,05029,33829,10625,50325,22325,357
TOTAL ASSETS:40,35039,98740,66140,05438,69238,84839,409
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,3509921,2371,1961,221937862
Accounts payable602464683556572415439
Accrued liabilities85129100841518063
Employee-related liabilities525219266197400318231
Other undisclosed accounts payable and accrued liabilities13718018836098124129
Debt760  93   
Other undisclosed current liabilities1018091,1395721,2751,291848
Total current liabilities:2,2111,8022,3761,8622,4952,2281,710
Noncurrent Liabilities
Long-term debt and lease obligation9,87210,16510,0039,2027,1477,3447,997
Long-term debt, excluding current maturities8,7379,0048,8137,9887,1477,3447,997
Operating lease, liability1,1351,1601,1901,214   
Liabilities, other than long-term debt    598757
Derivative instruments and hedges, liabilities    598757
Other undisclosed noncurrent liabilities (1,160)(1,190)    
Total noncurrent liabilities:9,87210,16510,0039,2027,2057,4318,054
Total liabilities:12,08311,96712,37911,0649,7019,6599,764
Stockholders' equity
Stockholders' equity attributable to parent28,26628,02128,28128,99028,99129,18929,645
Common stock730730730730730730730
Treasury stock, value(175)(188)(188)(188)(188)(196)(196)
Additional paid in capital31,37231,32831,26631,20931,13231,04830,979
Accumulated other comprehensive loss    (44)(65)(43)
Accumulated deficit(3,660)(3,849)(3,526)(2,761)(2,638)(2,328)(1,825)
Total stockholders' equity:28,26628,02128,28128,99028,99129,18929,645
TOTAL LIABILITIES AND EQUITY:40,35039,98740,66140,05438,69238,84839,409

Income statement (P&L) ($ in thousands)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues3,7433,7232,9664,9103,6322,9702,710
Cost of revenue
(Cost of Goods and Services Sold)
(2,122)(2,000)(1,683)(2,674)(1,794)(1,519)(1,461)
Gross profit:1,6211,7221,2832,2361,8381,4511,249
Operating expenses(2,255)(1,974)(1,975)(2,039)(2,081)(1,881)(1,796)
Operating income (loss):(634)(252)(691)197(242)(430)(547)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
828(71)(75)(334)(72)(65)(65)
Interest and debt expense492(76)(77)(347)(99)(107)(112)
Income (loss) from continuing operations before equity method investments, income taxes:685(399)(843)(484)(413)(602)(724)
Other undisclosed income (loss) from continuing operations before income taxes(492)767734799107112
Income (loss) from continuing operations before income taxes:193(323)(766)(137)(314)(495)(612)
Income tax expense (benefit)(4)  154(7)(15)
Net income (loss) available to common stockholders, diluted:189(323)(766)(122)(310)(503)(627)

Comprehensive Income ($ in thousands)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):189(323)(766)(122)(310)(503)(627)
Other comprehensive income (loss)   4421(22)(46)
Comprehensive income (loss), net of tax, attributable to parent:189(323)(766)(78)(289)(525)(673)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: